„DON“ compounds

Boc-DON-Gln-Ile-Val-OMe, Boc-DON

10 mg 400 € available

Art. No. B003
Synonym tert.-Butyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-LGlutaminyl-L-Isoleucinyl-L-Valinmethylester
Molecular Formula C28H47N7O9
Molecular Weight 625.7
Purity by HPLC >95 % (HPLC)
Appearance yellow solid
Solubility 100 μM in 0.1% (v/v) DMSO / aqueous buffers.
Pre-dissolve the complete 10 mg (adjust to the weight given on the vial) in 160 μL DMSO. Take e.g. 10 μL of the 100 mM stock solution and add 9990 μL buffer or assay components to obtain your final assay solution (100 μM).
DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Alternatively, higher concentrations of 1.5 mM in 2% (v/v) DMSO / aqueous buffers are feasible.
Application Irreversible inhibitor of tissue transglutaminase; IC50 ~ 0.3 µM
Storage store at -20°C, desiccate
Reference(s) Verhaar et al., Neurochem. Int. 2011, 58:785-93
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
McConoughey et al., EMBO Mol. Med. 2010, 2:1-22
Zeugolis et al., J. Biomed. Mater. Res. 2010, 15:1310-20
Kristen et al., Circ. Res. 2008, 102:529-37
Mádi et al., Anal. Biochem. 2005, 343:256-62
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy